BioCentury
ARTICLE | Clinical News

Inotuzumab ozogamicin: Phase III final data

June 27, 2016 7:00 AM UTC

Final data from the open-label, international Phase III INO-VATE ALL (Study B1931022) trial in 326 patients with relapsed or refractory CD22-positive ALL showed that once-weekly 0.5-0.8 mg/m 2 IV inot...